Incyte Corporation, founded in 2002 and headquartered in Wilmington, Delaware, is a public biopharmaceutical company traded on Nasdaq under the symbol INCY and is a component of the S&P 500. The company’s core mission is to discover, develop, and commercialize proprietary small molecule drugs with a primary focus on oncology. Incyte aims to provide innovative solutions for patients through scientific excellence. Their product portfolio includes several oncology therapies designed to address unmet medical needs.
Notable figures affiliated with Incyte include Hervé Hoppenot, who serves as CEO, chairman, and president. The company has achieved significant financial milestones, reporting a revenue of $3.69 billion, an operating income of $621 million, and a net income of $598 million in 2023. With total assets amounting to $6.78 billion and equity of $5.19 billion, Incyte has made a substantial impact in the pharmaceutical industry, driven by its commitment to innovation and patient support.
